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Enhanced Recovery after Surgery (ERAS) is an evidence-based approach that aims to reduce narcotic use and
maintain anabolic balance to enable full functional recovery. Our primary aim was to determine the effect of
ERAS on narcotic usage among patients who underwent exploratory laparotomy by gynecologic oncologists. We
characterized its effect on length of stay, intraoperative blood transfusions, bowel function, 30-day readmissions,
and postoperative complications. A retrospective cohort study was performed at Abington Hospital-Jefferson
Health in gynecologic oncology. Women who underwent an exploratory laparotomy from 2011 to 2016 for
both benign and malignant etiologies were included before and after implementation of our ERAS protocol.
Patients who underwent a bowel resection were excluded. A total of 724 patients were included: 360 in the nonERAS and 364 in the ERAS cohort. An overall reduction in narcotic usage, measured as oral morphine milli
equivalents (MMEs) was observed in the ERAS relative to the non-ERAS group, during the entire hospital stay
(MME 34 versus 68, p < 0.001 and within 72 h postoperatively (MME 34 versus 60, p < 0.005). A shorter length
of stay and earlier return of bowel function were also observed in the ERAS group. No differences in 30-day
readmissions (p = 0.967) or postoperative complications (p = 0.328) were observed. This study demonstrated
the benefits of ERAS in Gynecologic Oncology. A significant reduction of postoperative narcotic use, earlier
return of bowel function and a shorter postoperative hospital stay was seen in the ERAS compared to traditional
perioperative care.

1. Introduction
Surgical stress induces a complex inflammatory response that can
lead to significant morbidity for the patient (Kehlet, 1997; Kehlet and
Wilmore, 2002). This response is marked by production of catabolic
hormones and cytokines that results in increased tissue demand and
organ dysfunction (Kehlet and Wilmore, 2002). Enhanced Recovery
after Surgery (ERAS) is an evidence-based pathway that has replaced
traditional perioperative care. Key tenets of this protocol aim to atten
uate hypothermia, hypervolemia, starvation and immobilization that
may further compound this response to surgical stress (Kehlet, 1997;
Kehlet and Wilmore, 2002).
ERAS is a multimodal, multidisciplinary approach that has become
standard of care at most surgical centers. This includes pre-, intra-, and
post-operative tools used to hasten full functional recovery after surgery

(Nelson et al., 2019). Benefits of ERAS have largely been studied in
colorectal surgery (Lee et al., 2020; Varadhan et al., 2010; Lohsiriwat,
2019; Bagnall et al., 2014) and remain relatively undescribed in gyne
cologic oncology.
While the basic principles of ERAS involve early feeding, venous
thromboembolism (VTE) prophylaxis, goal-directed fluid therapy and
multimodal analgesia, specific protocols remain heterogeneous across
institutions (Nelson et al., 2019; Helou et al., 2020). Variations of ERAS
protocols in Gynecologic Oncology have included differences in VTE
prophylaxis, local anesthesia with transversus abdominis plane blocks,
local liposomal bupivacaine, subarachnoid blocks or thoracic epidural
anesthesia and postoperative pain control regimens (Kalogera et al.,
2013; Kalogera et al., 2016; Bergstorm et al., 2018).
The data surrounding implementation of ERAS protocols has sug
gested an overall reduction of narcotic usage (Kalogera et al., 2013;
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Kalogera et al., 2016; Barber and Van Le, 2015). However, due to a lack
of consistent protocols, the true reduction of narcotic use among gyne
cologic oncology patients has yet to be described with ERAS at our
institution. Further, less conclusive data is available for other periop
erative outcomes in Gynecologic Oncology. Some studies demonstrate
no decrease in overall length of hospitalization or postoperative com
plications (Bergstorm et al., 2018; Wijk et al., 2014). Others show that it
can result in a shorter length of stay, reduction in postoperative com
plications, earlier return of bowel function and decrease in readmissions
(Kalogera et al., 2013; Wijk et al., 2014; Boitano et al., 2018; Marx et al.,
2006). This demonstrates the importance of studying institution-based
ERAS protocols established in Gynecologic Oncology and subsequent
effect on patient outcomes.
The aim of this study is to provide a detailed analysis of the effect of
an implemented ERAS protocol established at our large, communitybased hospital in Gynecologic Oncology and its effects on periopera
tive narcotic usage. We also characterize differences in length of hospital
stay, return of bowel function, intraoperative use of blood transfusions,
30-day readmissions and postoperative complications.

Table 1
ERAS protocol.
Preoperative
Education
Nutrition/fluid
management

Antibiotic
prophylaxis/
drains/
catheters

- Verbal patient
education on ERAS
protocols
- List of high
carbohydrate
foods for
preoperative
carbohydrate
intake
- Encouraged to
consume clear
liquids 2 h prior to
surgery
- Preoperative
chlorhexidine
wash usually
performed day
prior to surgery

2. Methods
A retrospective cohort study was performed at a single, high-volume
community-based hospital. This study was approved via expedited re
view by the Institutional Review Board at Abington Hospital-Jefferson
Health (study #19-057). Our ERAS protocol was established in 2014
by the division of Gynecologic Oncology along with operating room staff
members, oncology nurses, and a group of anesthesiologists via a
multidisciplinary conference. This protocol was developed with the use
of evidence-based recommendations from the ERAS Society, but also
accounted for issues that are unique to Gynecologic Oncology patients
and hospital-specific capabilities (Table 1).
Women over age 18 undergoing exploratory laparotomy for all gy
necologic indications through the Department of Gynecologic Oncology
were included in this study. Patients both prior to ERAS implementation
from 2011 to 2013 and after ERAS implementation from 2014 to 2016 at
our institution were included in this study and compared as separate
cohorts. All patients who underwent minimally invasive surgeries and
those with non-gynecologic primary cancers were excluded. Patients
who underwent any type of bowel resection did not receive the ERAS
protocol and were thereby excluded from both cohorts. To limit selec
tion bias and better standardize the patients studied, those who under
went bowel resections were excluded due to intraoperative involvement
by other departments who did not adopt similar ERAS principles. In
addition, a large portion of patients in this group were admitted to the
intensive care unit and kept NPO in this group due to exceptional sur
gical complexity. Patients who received continuous epidurals were also
excluded as this was not part of our final ERAS protocol.
Relevant data were abstracted from electronic medical records of all
patients that met inclusion criteria. Complexity of procedure was
determined internally and was stratified as low, moderate, or high
which reflected the surgical procedure required. Low complexity cases
consisted of any unilateral/bilateral salpingo-oophorectomy, total
abdominal hysterectomy or lysis of adhesions. Any surgery that included
an appendectomy or pelvic and/or paraaortic lymph node dissection
was categorized as moderate. High complexity cases involved any upper
abdominal surgery such as splenectomy, liver surgery, or diaphragm
stripping.
Postoperative narcotic use was the primary outcome and defined as
any opioid medication administered after surgical stop time and during
length of hospitalization. Narcotic use was quantified for the entire
duration of initial hospitalization and 72 h postoperatively using oral
morphine milligram equivalents (MME) with standard conversion ta
bles. Length of hospital stay was calculated as the number of post
operative days and included the day of primary surgery. Days of
readmission to the hospital were not included in this measure. All

Medications/
pain regimen

Activity

Preoperative
bundle:
- celecoxib 200 mg
PO
- acetaminophen
1000 mg PO
- Gabapentin 600
mg PO
- Heparin 5000
units SQ

Intraoperative

Postoperative

- Goal directed
fluid
administration
with avoidance of
over-resuscitation
- avoidance of NG
tube placement

Day 0: IVF at 40
mL/hr, clear liquid
diet, Ensure as
needed
Day 1: Advance to
transitional diet
Day 2: Maintain
regular diet

- Cefazolin +/metronidazole
(Gentamycin,
Clindamycin +/metronidazole for
PCN allergy)
- Limit drains &
nasogastric tubes
- maintain
normothermia with
blanket warmer
application

- Day 1:
postoperative foley
catheter removal

- preoperative IV
steroids and 5-HT3
inhibitor
- intravenous
anesthesia at
discretion of
anesthesiologist
- TAP block after
surgery close

- avoidance of PCA
- multimodal pain
regimen:
Ibuprofen 600 mg
PO Q6H
Acetaminophen
1000 mg PO Q6H
Hydromorphone 2
mg PO Q4H PRN
Hydromorphone
0.4
mg IV Q3H PRN
- LMWH
prophylaxis
- Day 0: Sit on edge
of bed or chair
- Day 1: Out of bed
with early
ambulation
- Day 2 to
discharge:
Encourage labs
around hallway

h, hour; mg, milligrams; IV, intravenous; PO, per os; SQ, subcutaneous; TAP,
transversus abdominis plane; LMWH, low molecular weight heparin.

readmissions within 30 days of initial surgery were calculated as a
percentage of the total in each cohort group. Intraoperative character
istics including estimated blood loss and intravenous fluid resuscitation
volume were documented in milliliters. Return of bowel function was
defined as initial onset of flatus or bowel movement. Patients were
generally discharged once all postoperative milestones were met,
including sufficient pain control with oral medications, return of bowel
function, ability to tolerate a diet and no immediate suspicion of
complications.
Categorical variables were summarized using actual counts (per
centages) and continuous variables using median due to the non-normal
distribution of data presented. The Mann Whitney U test was used for all
continuous variables. The chi-squared test was used to analyze all cat
egorical data. A p-value <0.05 denotes statistical significance. IBM SPSS
software was used for statistical analysis.
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3. Results

complications did not differ (p = 0.328). Intraoperative characteristics
also differed substantially between the two groups (Table 3). Intra
operative fluid volume administered was significantly less, 2900 mL in
ERAS and 3500 mL in non-ERAS cohort (p < 0.001). Estimated blood
loss was 250 mL and 300 mL in ERAS and non-ERAS cohorts, respec
tively (p = 0.015). Consistent with this, intraoperative blood trans
fusions were used less frequently in the ERAS cohort (9.1% versus
15.6%, p = 0.008). Drain placement was also significantly less frequent
in the ERAS cohort (2.5% versus 9.2%, p = 0.008).
Given that ERAS is a multidisciplinary protocol, a compliance anal
ysis over the first 2 years of implementation (2014–2016) was retro
spectively performed through data available via the electronic medical
record (EMR) system (Table 4). Compliance with preoperative ERAS
components such as administration of celecoxib, gabapentin and acet
aminophen ranged from 65 to 70%; this was limited by patient specific
contraindications to these medications. In the ERAS cohort, 69.8% of
patients received a postoperative transversus abdominis plane (TAP)
block performed by an anesthesiologist. The highest rate of compliance
was with the postoperative components of the ERAS protocol including
96.4% for scheduled ibuprofen and 97.8% for oral or IV hydromorphone
for breakthrough pain after primary surgery. Overall, the preoperative
ERAS component had a much lower compliance rate with the exception
of DVT prophylaxis. All patients received preoperative DVT prophylaxis
in the form of heparin 5,000 units or low molecular weight heparin 40
mg administered subcutaneously. Patients who were on preoperative

A total of 724 women met inclusion criteria for this analysis; 360
patients in the traditional perioperative care cohort from 2011 to 2013
and 364 enhanced recovery cases from 2014 to 2016 were included
(Fig. 1). Eight patients were excluded for non-gynecologic primaries, ten
for incomplete data in the electronic system, one patient under age 18,
and 117 patients with bowel resections, and 14 patients that received
continuous epidurals were excluded. The average age was similar be
tween the two cohorts. Overall, no differences in baseline characteristics
between the ERAS and non-ERAS cohorts including BMI, race, diabetes,
hypertension, major cardiovascular incident, smoking status, malignant
versus benign disease, complexity of procedure, wound class and patient
disposition were observed (Table 2).
Postoperative opioid use decreased by 50% in the ERAS population
relative to the non-ERAS group for the entire duration of hospital stay
(median, 34 MME versus 68 MME, p < 0.001) (Fig. 2), and decreased by
43% within the first 72 h (h) after surgery (ERAS, 34 MME and nonERAS, 60 MME; p < 0.000).
Length of hospital stay differed by an average of 1 day (median of 4
days in non-ERAS versus 3 in ERAS, p < 0.001) (Table 3). More than
50% of patients were discharged between 0 and 3 days in the ERAS
group relative to only 19% in non-ERAS (p < 0.001) (Table 3). Patients
experienced a 1-day earlier return of bowel function (p < 0.001). The
rate of 30-day readmissions (p = 0.967) and postoperative

Fig. 1. Consort diagram of study population.
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Table 2
Patient demographics.

Age, median
BMI, median
Race/ethnicity
White
Black
Asian
Hispanic
Diabetes
Hypertension
Major cardiovascular incident1
Smoker
Current
Former
Never
Malignant disease
Complexity of procedure
Lowa
Moderateb
Highc
Disposition
Home
Skilled nursing facility
Acute rehab2
Wound class
I (clean)
II (clean-contaminated)

Non-ERAS
N = 360

ERAS
N = 364

p-value

56
28.4

57
28.6

284 (78.9)
56 (15.5)
14 (3.8)
6 (1.7)
52 (14.4)
145 (40.3)
12 (3.3)

301 (82.7)
36 (9.9)
16 (4.4)
11 (3.0)
40 (11.0)
130 (35.7)
6 (1.7)

0.142
0.531
0.093

36 (10.0)
62 (17.2)
262 (72.8)
186 (51.7)

38 (10.4)
83 (22.8)
243 (66.8)
190 (52.2)

186 (51.7)
110 (30.6)
64 (17.8)

178 (48.9)
100 (27.5)
86 (23.6)

307 (85.3)
25 (6.9)
28 (7.8)

314 (86.3)
20 (5.5)
30 (8.3)

54 (15.0)
306 (85.0)

48 (13.2)
316 (86.8)

Table 3
Perioperative patient outcomes.
Length of hospital stay, median days
(IQR)
Intraoperative measures, median
Surgical time, min
Intraoperative fluid volume, mL
Estimated blood loss, mL
Intraoperative blood Transfusion (%)
Postoperative complications N, (%)
Bladder injury
Postoperative ileus
Colonic injury
Postoperative infection
Incisional hematoma
Wound dehiscence
Return of flatus (median days) (IQR)
Drain placement (%)
Optimal debulking (%)
Length of hospital stay, N (%)
0 – 3 days

0.163
0.206
0.154
0.150

0.886
0.145

0.547

0.483

BMI, body mass index.
Data are n (%) shown above unless otherwise indicated.
1
Includes heart failure, acute pulmonary embolism, stroke or acute myocar
dial infarction.
a
Includes unilateral/bilateral salpingoophorectomy, total abdominal hyster
ectomy, lysis of adhesions.
b
Includes appendectomy, pelvic and/or paraaortic lymph node dissection.
c
Includes diaphragm stripping, liver surgery, and other upper abdominal
surgery.
2
Performed at a designated facility or via home care.

4+ days
Return of bowel function (flatus), N
(%)
0 – 3 days
4+ days

Non-ERAS
4 (4 – 5)

ERAS
3 (3 – 4)

p-value
<0.001*

171
3500
300
56 (15.6)
17 (4.7)
4 (1.1)
5 (1.3)
5 (1.3)
–
–
1 (0.2)
3 (3-4)
33 (9.2)
171 (91)

169
2900
250
33 (9.1)
12 (3.3)
4 (1.1)
5 (1.4)
1 (0.3)
1 (0.3)
1 (0.3)
–
2 (2-3)
9 (2.5)
166 (92.7)

0.989
<0.001*
0.015*
0.008
0.328

70 (19.4%)
290
(80.6%)

185
(50.8%)
179
(49.2%)

300
(92.9%)
23 (7.1%)

249
(75.9%)
79 (24.0%)

<0.001*
0.001*
0.534
0.001*

0.001*

Perioperative patient outcomes between non-ERAS and ERAS cohorts reported
as N (%) or median (IQR = interquartile range), as appropriate.
Return of bowel function was not recorded for several patient charts and
therefore, these charts were excluded in this specific category.
mL, milliliters.
min, minutes.

Fig. 2. Postoperative narcotic use. Differences are in median postoperative use before and after ERAS protocol implementation during patients’ entire hospital stay
after surgery (p-value < 0.001) and 72 h postoperatively (p-value < 0.001). *denotes significance. h, hours.
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significant difference in our protocol compared with the published
literature.
Interestingly, our study also found a higher intraoperative EBL by an
average of 50 mL in the non-ERAS cohort. It is unclear whether this is
clinically significant. However, we also noted an increased use of
intraoperative blood transfusions in the non-ERAS group. Of note, both
our ERAS and non-ERAS cohorts received preoperative VTE prophylaxis
at similar rates as our institution had adopted this measure before the
complete ERAS protocol. While some studies have theorized an increase
in surgical blood loss with preoperative NSAID use, a recent systematic
review provides evidence that perioperative COX-2 inhibitor use did not
increase intraoperative blood loss or rate of blood transfusions (Souter
et al., 1994; Cawthorn et al., 2012; Teerawattananon et al., 2017;
Ljungqvist et al., 2017). Our findings are also consistent with several
other studies that demonstrate lower blood loss and transfusion rates in
ERAS groups (Kalogera et al., 2013; Pang et al., 2018).
While this present study includes a transparent, critical analysis of
ERAS protocol implementation over a large study period, there are
important limitations to this study. The retrospective design limits
analysis of subjective patient outcomes. Specifically, patient reports of
adequate pain control, hunger, thirst and general satisfaction with im
mediate postoperative recovery could not be measured. Areas of
improvement within our protocol implementation could further include
standardization of preoperative carbohydrate loading and routine audits
to ensure compliance given the multidisciplinary nature of ERAS
(Bergstorm et al., 2018; Bisch et al., 2018). During a portion of the study
period, specifically after 2014, our group conducted a randomized
control trial that measured pain outcomes with use of liposomal bupi
vacaine versus bupivacaine for TAP blocks. Results from this study failed
to reveal any significant differences in length of stay but did show some
reduction in narcotic use. As we are unable to control for this during the
current study, it represents a weakness for the current analysis.(Ching
et al., March 2018) Lastly, patients who underwent a bowel resection
were not included as noted above in this study. Further studies can
include patients who underwent bowel resection as all departments have
now adopted consistent ERAS principles at our institution.
Despite these limitations, we were able to show a significant reduc
tion in overall postoperative narcotic use with the implementation of
our ERAS protocol. Patients experienced an earlier return of bowel
function, shorter duration of hospitalization, and decreased use of
intraoperative blood transfusions. Further strengths of our analysis
include the heterogeneity of our population and large sample size. We
were also able to perform a compliance analysis, which showed a high
rate of adherence to the ERAS protocol established at our institution.
The preoperative components of our ERAS protocol had the lowest
compliance rates; this may be due to patient specific allergies or in
tolerances to medications containing sulfa or acetaminophen, which
limit utility of preoperative analgesics inherent to our protocol.
Furthermore, preoperative components of ERAS at our institution are
typically administered by preoperative nursing staff; it is certainly
possible that medications may have simply not been give due to
miscommunication or misplaced orders within the electronic medical
system (EMR). Therefore, this identifies an area for quality improvement
to increase compliance with the preoperative components of ERAS in
our Gynecologic Oncology department.
In conclusion, our ERAS protocol for patients undergoing an
exploratory laparotomy in Gynecologic Oncology reduced opioid con
sumption and produced favorable patient outcomes. This data provides
additional support for adoption of ERAS in Gynecologic Oncology.
Further studies are necessary to determine how this may affect longterm opioid use and the ability to initiate intended adjuvant cancer
therapy such as chemotherapy or radiation.

Table 4
Compliance analysis for ERAS components.
ERAS component
Preoperative
Celecoxib
Gabapentin
Acetaminophen
Heparin
Intraoperative
Regional Block (TAP)
Postoperative
Ibuprofen Q6H
Hydromorphone PO/IV PRN

% compliance
65.1
70.1
68.1
95.8
69.8
96.4
97.8

TAP, transversus abdominis plane block.

therapeutic anticoagulation were counseled to discontinue this medi
cation according to the current guidelines established by the American
College of Surgeon’s for perioperative management of antithrombotic
medication (Hornor et al., 2018).
4. Discussion
Our study adds to the growing body of literature demonstrating
effectiveness of ERAS protocol implementation on a Gynecologic
Oncology service. Implementation of our ERAS protocol resulted in
significant reduction of total postoperative narcotic usage during the
entire hospitalization and 72 h after surgery in patients undergoing
exploratory laparotomy. There was also a significant reduction in
overall PCA use. This is consistent with most retrospective studies
established in Gynecologic Oncology. (Kalogera et al., 2013; Kalogera
et al., 2016; Wijk et al., 2014; Barber and Van Le, 2015; Boitano et al.,
2018)
An overall 1-day reduction in LOS and 1-day earlier return of bowel
function was also observed in our ERAS cohort. While most evidence in
Gynecologic Oncology suggests reduction in overall length of stay,
(Kalogera et al., 2016; Bergstorm et al., 2018; Wijk et al., 2014; Gerardi
et al., 2008) some have shown no difference (Bergstorm et al., 2018).
Furthermore, some studies show no difference in postoperative com
plications (Kalogera et al., 2016; Bergstorm et al., 2018; Wijk et al.,
2014; Eberhart et al., 2008) and this is consistent with data presented
here. However, Boitano et al. demonstrate a reduction in postoperative
ileus(Boitano et al., 2018), while Marx et al. showed a decrease in other
major surgical complications (Marx et al., 2006). While the tenets of
early recovery remain similar, actual ERAS protocols vary across in
stitutions in Gynecologic Oncology (Kalogera et al., 2016; Bergstorm
et al., 2018; Wijk et al., 2014). A 2014 review of enhanced recovery in
gynecologic oncology identified seven retrospective studies that utilized
various perioperative ERAS components (Nelson et al., 2014). Due to
differences noted in outcomes and protocols, it is essential to perform
institution-based studies to analyze the effects of specific protocol
implementation.
It is important to highlight specific aspects of our ERAS protocol that
may differ from those protocols discussed in Gynecologic Oncology
literature thus far. Specifically, while use of TAP blocks have shown a
reduction in immediate intra- and post-operative opioid use in open
abdominal surgeries (Bhattacharjee et al., 2014; McDonnell et al., 2007;
Carney et al., 2010; Peltrini et al., 2020), administration of TAP blocks
remains controversial in Gynecologic Oncology (Nelson et al., 2019;
Bisch et al., 2019; Chang et al., 2018). To the best of our knowledge,
most large retrospective studies of ERAS in Gynecologic Oncology have
incorporated use of epidurals, incisional liposomal bupivacaine or sacral
nerve blocks for multimodal pain control regimens (Nelson et al., 2019;
Boitano et al., 2018; Kalogera et al., 2013; Kalogera et al., 2016; Berg
storm et al., 2018; Wijk et al., 2014; Modesitt et al., 2016; Wijk et al.,
2019; Bisch et al., 2018). Though our study does not specifically address
TAP block use as an independent variable, this does represent a

5. Presentations
Oral presentation at the Mid-Atlantic Gynecologic Oncology meeting
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in Charlotte, North Carolina (October 24–26, 2019).
Poster at the Society of Gynecologic Oncology meeting in Toronto,
Ontario, Canada (March 28–31, 2020) Cancelled due to COVID-19
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